Structural Intervention

Lars Søndergaard, Darren Mylotte, Andreas Rück, et al

Watch time: 2h 17m (7 videos)

Francesco Maisano, Anita W Asgar, , et al

Watch time: 59m 21s (5 videos)


Valve replacement surgery can be an effective, lifesaving treatment option for people with aortic or mitral valve diseases.

Aortic valve replacement is often required in older patients but the surgical risk is often extremely high. Transcatheter aortic valve implantation (TAVI) is an established therapy for intermediate and high surgical risk patients with symptomatic severe aortic valve stenosis.

Approximately 1.8% of the US population has mitral valve disease, and an estimated 106,000 surgeries per year are for the treatment of valvular heart disease. The durability of surgical mitral valve repairs and replacement are limited. There is a 25% rate of significant mitral regurgitation recurrence in surgical repairs at 2 years and a 44% rate of primary valvular failure at 15 years, leaving the patient with either symptomatic mitral regurgitation, stenosis or both.


CAD in Patients Undergoing TAVI


29 September 2022


Interventional Cardiology 2022;17:e13.

TAVI for Pure Aortic Regurgitation With Dedicated Devices


21 July 2022


Interventional Cardiology 2022;17:e11.

Impella-supported MitraClip in Cardiogenic Shock Patients Complicated With High-grade Mitral Regurgitation


28 June 2022


Interventional Cardiology Review 2022;17(Suppl 1):26.

Balloon Pre-dilation and Post-dilation in TAVR


12 October 2021


Interventional Cardiology 2021;16:e28.